FDA aims to speed clinical trials, improve device safety through post-market evaluation, but funding a hurdle -

February 16, 2016 – FDA’s device center chief Jeff Shuren, in an interview with Inside Health Policy, highlighted the benefit a robust National Device Evaluation System could have in bolstering the agency’s ability to monitor devices in real-time to better inform the risk-benefit profile of approved products. Such a system, he said, could also help in the premarket approval phase to reduce the clinical trial burden on manufacturers and get products to market faster.

Cancer Moonshot misses the target -

February 11, 2016 – Hospitals don’t have much to gain from the moonshot, at least in the short run. There are lot of other pressing, fixable problems with cancer care that the Obama administration’s effort won’t address.

Breast implants and mammography: what we know and what we don’t know -

There has been a lot of attention given to mammography screening in recent years. Some of this information has been confusing to women—at what age should I first have a mammogram, how frequently should I have repeat mammograms, and are mammograms even effective? These are questions that women both with and without breast implants have been trying to understand. The latest study from FDA scientists helps to answer these questions.

Phthalates Q&A -

Answers to common questions about phthalates and the possible risks.